This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Iwanuma, Y. Articles by Bankert, R. B. Search for Related Content PubMed PubMed Citation Articles by Iwanuma, Y. Articles by Bankert, R. B.

Antitumor Immune Response of Human Peripheral Blood Lymphocytes Coengrafted with Tumor into Severe Combined Immunodeficient Mice¹

Department of Molecular Immunology, Roswell Park Cancer Institute, New York State Department of Health, Buffalo. New York 14263

Here, it is established that human peripheral blood lymphocytes (HuPBLs), injected s.c. with a human lung tumor into severe combined immunodeficient (SCID) mice, engraft and display antitumor cytotoxic activity. Initial studies used HuPBLs from normal donors and an allogeneic tumor cell line derived from biopsy tissue of a patient with a squamous cell carcinoma of the lung. Evidence of HuPBL antitumor activity was revealed by a cell dose-dependent suppression of the tumor xenograft. Tumor suppression was shown to be dependent upon both CD8+ T cells and CD56+ natural killer cells in the donor HuPBLs. By titrating the antitumor activity of HuPBLs in SCID mice with and without cytokines, it was established that interleukin (IL)-12 enhanced the HuPBL-mediated tumor suppression and that IL-2 had a synergistic effect upon the IL-12 enhancement of cytotoxicity. Subsequent studies revealed that a lung cancer patient's PBLs also suppress the growth of the patient's (autologous) tumor when coinjected s.c. with the tumor cells into SCID mice. The patient's antitumor immunity was shown to be mediated by CD8+ T cells and CD56+ natural killer cells. The data presented here indicate that the s.c. coengraftment of HuPBLs and tumor into SCID mice represents a viable model with which to study (and to periodically monitor) patients' immune responses to their tumors for extended periods of time and suggest that this SCID/Winn assay could be used to evaluate novel immunotherapeutic approaches, such as bolus injections of cytokines, cytokine gene therapy, or vaccination strategies for the treatment of human cancer.

¹ This work was supported in part by United States Public Health Service Grant No. CA54491 and NIH Core Grant No. CA 16056.

² To whom requests for reprints should be addressed, at Department of Molecular Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263.

Received 11/15/96. Accepted 5/13/97.

This article has been cited by other articles:

				M. R. Simpson-Abelson, G. F. Sonnenberg, H. Takita, S. J. Yokota, T. F. Conway Jr., R. J. Kelleher Jr., L. D. Shultz, M. Barcos, and R. B. Bankert Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2R{gamma}null Mice J. Immunol., May 15, 2008; 180(10): 7009 - 7018. [Abstract] [Full Text] [PDF]

				M. R. Nazareth, L. Broderick, M. R. Simpson-Abelson, R. J. Kelleher Jr., S. J. Yokota, and R. B. Bankert Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells J. Immunol., May 1, 2007; 178(9): 5552 - 5562. [Abstract] [Full Text] [PDF]

				L. Broderick, S. J. Yokota, J. Reineke, E. Mathiowitz, C. C. Stewart, M. Barcos, R. J. Kelleher Jr., and R. B. Bankert Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-{gamma}, and Eradicate Tumor Cells J. Immunol., January 15, 2005; 174(2): 898 - 906. [Abstract] [Full Text] [PDF]

				F. Lozupone, D. Pende, V. L. Burgio, C. Castelli, M. Spada, M. Venditti, F. Luciani, L. Lugini, C. Federici, C. Ramoni, et al. Effect Of Human Natural Killer and {gamma}{delta} T Cells on the Growth of Human Autologous Melanoma Xenografts in SCID Mice Cancer Res., January 1, 2004; 64(1): 378 - 385. [Abstract] [Full Text] [PDF]

				S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma} J. Immunol., January 1, 2003; 170(1): 400 - 412. [Abstract] [Full Text] [PDF]

				N. K. Egilmez, S. D. Hess, F.-A. Chen, H. Takita, T. F. Conway, and R. B. Bankert Human CD4+ Effector T Cells Mediate Indirect Interleukin-12- and Interferon-{gamma}-dependent Suppression of Autologous HLA-negative Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Res., May 1, 2002; 62(9): 2611 - 2617. [Abstract] [Full Text] [PDF]

				O. Christ, S. Matzku, C. Burger, and M. Zöller Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo Clin. Cancer Res., May 1, 2001; 7(5): 1385 - 1397. [Abstract] [Full Text]

				M. Sugano, N. K. Egilmez, S. J. Yokota, F.-A. Chen, J. Harding, S. K. Huang, and R. B. Bankert Antibody Targeting of Doxorubicin-loaded Liposomes Suppresses the Growth and Metastatic Spread of Established Human Lung Tumor Xenografts in Severe Combined Immunodeficient Mice Cancer Res., December 1, 2000; 60(24): 6942 - 6949. [Abstract] [Full Text]

				S. D. Gillies, Y. Lan, J. S. Wesolowski, X. Qian, R. A. Reisfeld, S. Holden, M. Super, and K.-M. Lo Antibody-IL-12 Fusion Proteins Are Effective in SCID Mouse Models of Prostate and Colon Carcinoma Metastases J. Immunol., June 15, 1998; 160(12): 6195 - 6203. [Abstract] [Full Text] [PDF]